Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 17/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059418 | 0.82 | ALDH1A1 (0.72) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 | |
| SCHEMBL23456872 | 0.80 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 | |
| SCHEMBL5739160 | 0.79 | ALDH1A1 (1.00) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 | |
| SCHEMBL15555582 | 0.77 | ALDH1A1 (0.75) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 | |
| SCHEMBL12786989 | 0.77 | ALDH1A1 (0.75) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 | |
| SCHEMBL3583405 | 0.77 | ALDH1A1 (1.00) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 | |
| SCHEMBL601203 | 0.76 | ALDH1A1 (0.73) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 | |
| SCHEMBL2175455 | 0.76 | ALDH1A1 (0.63) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 | |
| SCHEMBL14075911 | 0.75 | ALDH1A1 (0.71) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 | |
| SCHEMBL8114982 | 0.75 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| CN-119798159-A | PAPD5 inhibitors and methods of use thereof | 儿童医学中心公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20220274928-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2022-09-01 | — | — | US | disclosed |
| EP-3959197-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020219729-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219729-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2137177-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, CDK1 | ALDH1A1 2075/4885TSHR 1239/4885HSD17B10 3362/4885 |
| US-20220274928-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | ALDH1A1 2425/4885TSHR 3815/4885HSD17B10 1532/4885 |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | ALDH1A1 2075/4885TSHR 1239/4885HSD17B10 3362/4885 |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | ALDH1A1 2075/4885TSHR 1239/4885HSD17B10 3362/4885 |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | POT1, PARP15, TERT | ALDH1A1 2425/4885TSHR 3815/4885HSD17B10 1532/4885 |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | ALDH1A1 2075/4885TSHR 1239/4885HSD17B10 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.